Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.52 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616354 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL28778918 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL8616352 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL18796608 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL12960576 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL25868822 | 1.00 | KMT2A (0.57) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL18796612 | 0.98 | BIRC2 (0.58) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL26292078 | 0.94 | BIRC2 (0.56) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL23834069 | 0.89 | KMT2A (0.60) | KMT2AMEN1FAAHMAPK1BIRC2 | |
| SCHEMBL23834071 | 0.89 | KMT2A (0.60) | KMT2AMEN1FAAHMAPK1BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511318-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2019-07-17 | — | — | EP | claimed |
| EP-3368508-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-09-05 | — | — | EP | claimed |
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-08-30 | — | — | US | claimed |
| WO-2017073797-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-05-04 | — | — | WO | claimed |
| EP-3511318-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3368508-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-08-30 | — | — | US | disclosed |
| WO-2017073797-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | MYD88, IL2, IFNG | KMT2A 3300/4885MEN1 3632/4885FAAH 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.